Seroprevalence of NMO-IgG Antibody in Neuromyelitis optica (NMO) and Its Specificity in Differentiating NMO from Other Demyelinating Diseases with Overlap Symptoms: An Iranian Experience
Neuromyelitis optica is an inflammatory demyelinating disease (IDD) of the CNS, which mainly affects optic nerve and spinal cord. Autoantibodies against aquaporin-4 also known as NMO-IgG have been implicated in the pathogenesis of NMO. We evaluated the sensitivity and specificity of NMO-IgG assay fo...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tehran University of Medical Sciences
2015-02-01
|
| Series: | Iranian Journal of Allergy, Asthma and Immunology |
| Subjects: | |
| Online Access: | https://ijaai.tums.ac.ir/index.php/ijaai/article/view/406 |
| _version_ | 1818926309315706880 |
|---|---|
| author | Mohammad Hossein Harirchian Abbas Tafakhori Shervin Taslimi Vajiheh Aghamollaii Reza Shahsiah Taha Gholipour Fatemezahra Mohammadi Ameneh Zare-Shahabadi |
| author_facet | Mohammad Hossein Harirchian Abbas Tafakhori Shervin Taslimi Vajiheh Aghamollaii Reza Shahsiah Taha Gholipour Fatemezahra Mohammadi Ameneh Zare-Shahabadi |
| author_sort | Mohammad Hossein Harirchian |
| collection | DOAJ |
| description | Neuromyelitis optica is an inflammatory demyelinating disease (IDD) of the CNS, which mainly affects optic nerve and spinal cord. Autoantibodies against aquaporin-4 also known as NMO-IgG have been implicated in the pathogenesis of NMO. We evaluated the sensitivity and specificity of NMO-IgG assay for diagnosing NMO patients and differentiating them from MS patients and those with undifferentiated IDD with overlap symptoms.Eligibility of patients with demyelinating disorders was evaluated based on physical examination, laboratory and imaging studies. Thirty four definite NMO patients (disregarding NMO-IgG status), 34 multiple sclerosis (MS) patients with a history of optic neuritis (ON) or myelitis that were matched for age and disease activity and 44 patients with ON or myelitis attacks fulfilling neither criteria of MS or NMO (NMO spectrum) were selected as undifferentiated group. NMO-IgG was measured in the serum of the included patients by cell-based indirect immunofluorescence assay (IFA). NMO antibody was positive in 11 (32.3%), and 4 (9.09%) patients in NMO and undifferentiated groups, but was undetctable in MS patients. NMO antibody was 32% (95%Cl: 19-49%) sensitive in detecting NMO patients. Its specificity in differentiating NMO from MS subjects was 100 % (95% Cl: 90-!00%). NMO antibody was 95% (95% Cl: 0.88-0.98) specific in differentiating NMOs from other demyelinating diseases. Our results showed that although NMO antibody is highly specific for NMO, current method of measuring it with cell-based IFA is not highly sensitive for diagnosing NMO patients. |
| first_indexed | 2024-12-20T02:55:04Z |
| format | Article |
| id | doaj.art-c2a3d98fd01d4c6f984e391cd20cf1d2 |
| institution | Directory Open Access Journal |
| issn | 1735-1502 1735-5249 |
| language | English |
| last_indexed | 2024-12-20T02:55:04Z |
| publishDate | 2015-02-01 |
| publisher | Tehran University of Medical Sciences |
| record_format | Article |
| series | Iranian Journal of Allergy, Asthma and Immunology |
| spelling | doaj.art-c2a3d98fd01d4c6f984e391cd20cf1d22022-12-21T19:55:56ZengTehran University of Medical SciencesIranian Journal of Allergy, Asthma and Immunology1735-15021735-52492015-02-01141371Seroprevalence of NMO-IgG Antibody in Neuromyelitis optica (NMO) and Its Specificity in Differentiating NMO from Other Demyelinating Diseases with Overlap Symptoms: An Iranian ExperienceMohammad Hossein Harirchian0Abbas Tafakhori1Shervin Taslimi2Vajiheh Aghamollaii3Reza Shahsiah4Taha Gholipour5Fatemezahra Mohammadi6Ameneh Zare-Shahabadi7Iranian Center of Neurological Research, Tehran University of Medical Sciences, Tehran, Iran.Iranian Center of Neurological Research, Tehran University of Medical Sciences, Tehran, Iran.Iranian Center of Neurological Research, Tehran University of Medical Sciences, Tehran, Iran.Iranian Center of Neurological Research, Tehran University of Medical Sciences, Tehran, Iran.Iranian Center of Neurological Research, Tehran University of Medical Sciences, Tehran, Iran.Partners MS Center, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.Iranian Center of Neurological Research, Tehran University of Medical Sciences, Tehran, Iran.Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.Neuromyelitis optica is an inflammatory demyelinating disease (IDD) of the CNS, which mainly affects optic nerve and spinal cord. Autoantibodies against aquaporin-4 also known as NMO-IgG have been implicated in the pathogenesis of NMO. We evaluated the sensitivity and specificity of NMO-IgG assay for diagnosing NMO patients and differentiating them from MS patients and those with undifferentiated IDD with overlap symptoms.Eligibility of patients with demyelinating disorders was evaluated based on physical examination, laboratory and imaging studies. Thirty four definite NMO patients (disregarding NMO-IgG status), 34 multiple sclerosis (MS) patients with a history of optic neuritis (ON) or myelitis that were matched for age and disease activity and 44 patients with ON or myelitis attacks fulfilling neither criteria of MS or NMO (NMO spectrum) were selected as undifferentiated group. NMO-IgG was measured in the serum of the included patients by cell-based indirect immunofluorescence assay (IFA). NMO antibody was positive in 11 (32.3%), and 4 (9.09%) patients in NMO and undifferentiated groups, but was undetctable in MS patients. NMO antibody was 32% (95%Cl: 19-49%) sensitive in detecting NMO patients. Its specificity in differentiating NMO from MS subjects was 100 % (95% Cl: 90-!00%). NMO antibody was 95% (95% Cl: 0.88-0.98) specific in differentiating NMOs from other demyelinating diseases. Our results showed that although NMO antibody is highly specific for NMO, current method of measuring it with cell-based IFA is not highly sensitive for diagnosing NMO patients.https://ijaai.tums.ac.ir/index.php/ijaai/article/view/406Demyelinating disordersDevic diseaseMultiple sclerosisNeuromyelitis optica |
| spellingShingle | Mohammad Hossein Harirchian Abbas Tafakhori Shervin Taslimi Vajiheh Aghamollaii Reza Shahsiah Taha Gholipour Fatemezahra Mohammadi Ameneh Zare-Shahabadi Seroprevalence of NMO-IgG Antibody in Neuromyelitis optica (NMO) and Its Specificity in Differentiating NMO from Other Demyelinating Diseases with Overlap Symptoms: An Iranian Experience Iranian Journal of Allergy, Asthma and Immunology Demyelinating disorders Devic disease Multiple sclerosis Neuromyelitis optica |
| title | Seroprevalence of NMO-IgG Antibody in Neuromyelitis optica (NMO) and Its Specificity in Differentiating NMO from Other Demyelinating Diseases with Overlap Symptoms: An Iranian Experience |
| title_full | Seroprevalence of NMO-IgG Antibody in Neuromyelitis optica (NMO) and Its Specificity in Differentiating NMO from Other Demyelinating Diseases with Overlap Symptoms: An Iranian Experience |
| title_fullStr | Seroprevalence of NMO-IgG Antibody in Neuromyelitis optica (NMO) and Its Specificity in Differentiating NMO from Other Demyelinating Diseases with Overlap Symptoms: An Iranian Experience |
| title_full_unstemmed | Seroprevalence of NMO-IgG Antibody in Neuromyelitis optica (NMO) and Its Specificity in Differentiating NMO from Other Demyelinating Diseases with Overlap Symptoms: An Iranian Experience |
| title_short | Seroprevalence of NMO-IgG Antibody in Neuromyelitis optica (NMO) and Its Specificity in Differentiating NMO from Other Demyelinating Diseases with Overlap Symptoms: An Iranian Experience |
| title_sort | seroprevalence of nmo igg antibody in neuromyelitis optica nmo and its specificity in differentiating nmo from other demyelinating diseases with overlap symptoms an iranian experience |
| topic | Demyelinating disorders Devic disease Multiple sclerosis Neuromyelitis optica |
| url | https://ijaai.tums.ac.ir/index.php/ijaai/article/view/406 |
| work_keys_str_mv | AT mohammadhosseinharirchian seroprevalenceofnmoiggantibodyinneuromyelitisopticanmoanditsspecificityindifferentiatingnmofromotherdemyelinatingdiseaseswithoverlapsymptomsaniranianexperience AT abbastafakhori seroprevalenceofnmoiggantibodyinneuromyelitisopticanmoanditsspecificityindifferentiatingnmofromotherdemyelinatingdiseaseswithoverlapsymptomsaniranianexperience AT shervintaslimi seroprevalenceofnmoiggantibodyinneuromyelitisopticanmoanditsspecificityindifferentiatingnmofromotherdemyelinatingdiseaseswithoverlapsymptomsaniranianexperience AT vajihehaghamollaii seroprevalenceofnmoiggantibodyinneuromyelitisopticanmoanditsspecificityindifferentiatingnmofromotherdemyelinatingdiseaseswithoverlapsymptomsaniranianexperience AT rezashahsiah seroprevalenceofnmoiggantibodyinneuromyelitisopticanmoanditsspecificityindifferentiatingnmofromotherdemyelinatingdiseaseswithoverlapsymptomsaniranianexperience AT tahagholipour seroprevalenceofnmoiggantibodyinneuromyelitisopticanmoanditsspecificityindifferentiatingnmofromotherdemyelinatingdiseaseswithoverlapsymptomsaniranianexperience AT fatemezahramohammadi seroprevalenceofnmoiggantibodyinneuromyelitisopticanmoanditsspecificityindifferentiatingnmofromotherdemyelinatingdiseaseswithoverlapsymptomsaniranianexperience AT amenehzareshahabadi seroprevalenceofnmoiggantibodyinneuromyelitisopticanmoanditsspecificityindifferentiatingnmofromotherdemyelinatingdiseaseswithoverlapsymptomsaniranianexperience |